Oracle Corporation finds itself navigating a critical juncture, caught between the explosive expansion of its cloud services and a rapidly escalating debt burden. Recent clarifications concerning its marquee client, OpenAI, alongside new healthcare sector contracts, have provided temporary relief for investors. However, profound questions linger over whether the company’s aggressively financed artificial intelligence expansion can ultimately translate into sustainable profits.
Operational Momentum and Clarified Timelines
On the operational front, Oracle continues to post formidable growth figures. For the second quarter of its fiscal year 2026, the company reported:
- Cloud infrastructure revenue of $4.1 billion, representing a 68% year-over-year increase.
- Total cloud revenue reaching $8.0 billion, up 34%.
- Remaining Performance Obligations (RPO) soaring to $523 billion, a rise of 438%.
- GAAP earnings per share of $2.10, climbing 91%.
The firm currently operates 147 data center regions, with an additional 64 under construction. Its infrastructure, particularly its proprietary RDMA networking technology designed for compute-intensive AI workloads, serves high-profile clients including xAI and Meta Platforms alongside OpenAI.
The recent rebound in investor sentiment was triggered by the company directly addressing concerns over its OpenAI partnership. Oracle contradicted a Bloomberg report suggesting potential delays in OpenAI projects stretching to 2028, asserting there have been no changes to the agreed schedule. This clarification offered significant reassurance to the market, which had grown anxious about execution risks tied to what is believed to be the largest cloud contract in Oracle’s history.
This point is crucial due to the sheer scale of the dependency: approximately $300 billion of Oracle’s total $523 billion in RPO is attributed to the ChatGPT developer. Such extreme client concentration has markedly heightened Wall Street’s nervousness in recent months.
Concurrently, Oracle announced further inroads in the healthcare sector, with institutions like Mt. San Rafael Hospital adopting Oracle Health and others migrating to Fusion Cloud Applications. These new deals contribute to operational growth, even if they do not dilute the overarching reliance on OpenAI.
Mounting Financial Pressures and Market Skepticism
Despite the robust top-line growth, Oracle has become a focal point for broader market concerns regarding the financial sustainability of massive AI investments. To fund its data center expansion, the company has issued roughly $26 billion in bonds this year alone. The consequences are visible in the credit markets: the spreads on its Credit Default Swaps have reached their highest level since 2009, signaling increased perceived credit risk.
Should investors sell immediately? Or is it worth buying Oracle?
The financial strain is evident on the balance sheet. Oracle’s total debt has surged by 40% to $124 billion. Furthermore, the company carries an additional $248 billion in off-balance-sheet leasing commitments. The operational cash outflow in the most recent quarter ballooned to $10 billion from $2.7 billion, resulting in a notably tighter free cash flow position compared to hyperscale competitors like Microsoft and Alphabet.
According to Gavan Nolan of S&P Global Market Intelligence, the heightened leverage makes the corporation riskier from a credit perspective. Morningstar analyst Luke Yang notes there is “very little room for error” in the company’s strategic execution. The core challenge is that Oracle must convert its substantial new data center investments into meaningful cash returns relatively quickly, all while many end-customers are still determining how to monetize AI applications profitably.
Leadership Shifts and Strategic Pivots
Adding another layer of uncertainty is a recent change in leadership. In late September, long-time CEO Safra Catz was succeeded by Co-CEOs Clay Magouyrk and Mike Sicilia. This transition during a period of heavy investment and market volatility is a factor investors are monitoring closely.
On a strategic level, Chairman Larry Ellison announced a shift toward “chip neutrality,” severing the company’s relationship with chip designer Ampere. This move followed Oracle realizing a $2.7 billion pre-tax gain from the sale of its stake in Ampere. While demonstrating flexibility in infrastructure strategy, it also raises questions about the long-term architectural roadmap for its data centers.
Valuation and the Road Ahead
Current valuations reflect the ambitious growth narrative already priced into the stock. Oracle trades at a price-to-earnings ratio of 36.1, which sits above the Nasdaq-100’s multiple of 32.1. With a market capitalization of approximately $550 billion, the share price would need to advance 82% to reach the $1 trillion milestone—a goal that appeared closer in September when its market value peaked near $940 billion.
The pivotal risk factor remains the deep entanglement with OpenAI’s fortunes. It is unclear whether the ChatGPT developer can achieve its ambitious revenue targets in a market where Google and others are exerting intense competitive pressure. Oracle has emphasized that its AI infrastructure could be repurposed for other clients if necessary. Nevertheless, the extent to which the pledged $300 billion in obligations will materialize as actual revenue remains an open question.
In recent trading, shares have shown some stabilization. After declining roughly 41% from its September peak, the stock currently trades at 167.76 Euros, slightly below the prior day’s close but still above its level at the start of the year. Given the potent mix of rapid growth, high leverage, and a premium valuation, Oracle is likely to remain a key barometer in the coming quarters for how much risk the market is willing to accept in pursuit of the AI promise.
Ad
Oracle Stock: Buy or Sell?! New Oracle Analysis from December 23 delivers the answer:
The latest Oracle figures speak for themselves: Urgent action needed for Oracle investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 23.
Oracle: Buy or sell? Read more here...
